SLS Invest AB today entered into an agreement with Biolin Scientific regarding the sale of Sophion Bioscience

Stockholm, July 6, 2011. Today, SLS Invest AB signed an agreement with Biolin Scientific AB, a subsidiary of Ratos AB, concerning the sale of SLS Invest’s 19.3 percent shareholding in Sophion Bioscience A/S. All remaining shareholders in Sophion has agreed to sell their shares at the same time. The sales price is DKK 155 million in total of which DKK 10 million depend on sales in 2011/12. The sale is expected to be concluded in Q3 2011.

Per Carendi, CEO of SLS Invest, comments:
"The sale of Sophion to Biolin Scientific will ensure the further development of Sophion's technology within electrophysiological recordings. We are pleased to have participated in bringing Sophion to the stage of increasing sales, profitability and positive cash flow. The sale is also an important step in restructuring SLS into an investment company where holdings of portfolio companies preferably exceed 50 percent."

SLS Invest will receive proceeds of approximately SEK 30 million for the sale of the company's shareholding, with a possibility of another SEK 2.5 million from an earn-out model.

For further information, please contact :
Henrik Lawaetz, Investment Manager SLS Invest, tel: +45 326 481 84

About SLS Invest
SLS Invest AB is a Scandinavian investor focusing on Life Sciences with offices in Stockholm and Copenhagen. We operate as an evergreen structure and seek significant ownership stakes in companies with a proven business model and innovative products addressing a significant medical need. Along with the SLS portfolio we manage the portfolios of KA Intressenter (Formerly KIF) and Innoventus AB. Assets under management are some M€ 160. The majority of our portfolio companies have products on the market with significant and rapidly growing revenues.